journal article·2025-06-09Open access

Changes in Generations of PAMAM Dendrimers and Compositions of Nucleic Acid Nanoparticles Govern Delivery and Immune Recognition

Yelixza I. Avila, Laura P. Rebolledo, Nathalia Leal Santos, Brandon Rawlins, Yasmine Radwan, Melanie Andrade-Muñoz, Elizabeth Skelly, Morgan R. Chandler, Luciana N. S. Andrade, Tae Jin Kim, Marina A. Dobrovolskaia, Kirill A. Afonin

Abstract

Nucleic acid nanoparticles (NANPs) are promising immune modulators due to their well-established structural properties and distinct structure-activity relationship with the immune system. We previously identified that NANPs' size, shape, composition, and type of delivery vehicle define their uptake by immune cells and subsequently induced cytokine profile. In this work, we examined the delivery efficiencies and immunological impacts of two representative NANPs─DNA cubes and RNA cubes─complexed with a benchmark delivery vehicle, Lipofectamine 2000 vs. different generations of amine-terminated poly(amidoamine) dendrimers. Using molecular dynamics simulations, we modeled dendrimer interactions with nucleic acid cargos. Next, we used traditional 2D and more recently established 3D cell cultures to assess dendrimers' influence on NANPs uptake. Immune activation was evaluated in several cell lines engineered with reporter genes driven by key immune signaling pathways. Specifically, HEK-lucia reporter cells were used to evaluate RIG-I activation, while THP1-Dual cells provided quantitative readouts for both IRF and NF-κB transcription factor activity. Our findings demonstrate that both dendrimer generation and NANP composition influence cellular uptake and immune responses. This study underscores the importance of formulation in shaping NANPs' biological properties and further advances the understanding of their immunological properties critical for the development of NANPs-based adjuvants.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: RNA Interference and Gene Delivery · Dendrimers and Hyperbranched Polymers · Advanced biosensing and bioanalysis techniques

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry

University of North Carolina at Charlotte

Center for Translational Research in Oncology (LIM24), Instituto do Câncer do Estado de São Paulo

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Comprehensive Center for Precision Oncology, Universidade de São Paulo

MIMETAS US, Inc

Department of Physical Sciences

West Virginia University Institute of Technology

Nanotechnology Characterization Laboratory, Cancer Research Technology Program

Frederick National Laboratory for Cancer Research

Funding

Division of Cancer Prevention, National Cancer Institute · U.S. Department of Health and Human Services · NSF

References (74)

Show source-provided references
1. 10.1038/nnano.2007.22310.1038/nnano.2007.223 ↗
2. 10.1517/14712598.2015.101479410.1517/14712598.2015.1014794 ↗
3. 10.3390/molecules2614423110.3390/molecules26144231 ↗
4. 10.1016/j.copbio.2019.10.01110.1016/j.copbio.2019.10.011 ↗
5. 10.1021/acs.nanolett.8b0128310.1021/acs.nanolett.8b01283 ↗
6. 10.1021/acsami.0c0710610.1021/acsami.0c07106 ↗
7. 10.1016/j.addr.2021.11383410.1016/j.addr.2021.113834 ↗
8. 10.3390/molecules2603065210.3390/molecules26030652 ↗
9. 10.1021/acsnano.0c1024010.1021/acsnano.0c10240 ↗
10. 10.1002/adfm.20220558110.1002/adfm.202205581 ↗
11. 10.1016/j.nano.2019.10209410.1016/j.nano.2019.102094 ↗
12. 10.1016/j.addr.2021.04.01110.1016/j.addr.2021.04.011 ↗
13. 10.1093/nar/gkaa90810.1093/nar/gkaa908 ↗
14. 10.1002/smll.20170125510.1002/smll.201701255 ↗
15. 10.1016/j.omtn.2020.02.01110.1016/j.omtn.2020.02.011 ↗
16. 10.3389/fimmu.2023.105355010.3389/fimmu.2023.1053550 ↗
17. 10.1021/acsami.3c1777910.1021/acsami.3c17779 ↗
18. 10.1016/j.addr.2021.11390810.1016/j.addr.2021.113908 ↗
19. 10.2217/nnm.11.10510.2217/nnm.11.105 ↗
20. 10.1111/joim.1228010.1111/joim.12280 ↗
21. 10.1016/j.apmt.2018.05.00210.1016/j.apmt.2018.05.002 ↗
22. 10.1021/acs.bioconjchem.5b0003110.1021/acs.bioconjchem.5b00031 ↗
23. 10.1073/pnas.08201389910.1073/pnas.082013899 ↗
24. 10.1016/j.ccr.2020.21346310.1016/j.ccr.2020.213463 ↗
25. 10.1002/jps.2025110.1002/jps.20251 ↗
26. 10.2174/138161282366617030915195810.2174/1381612823666170309151958 ↗
27. 10.3389/falgy.2023.112601210.3389/falgy.2023.1126012 ↗
28. 10.3390/molecules2104042810.3390/molecules21040428 ↗
29. 10.2217/nnm.13.13710.2217/nnm.13.137 ↗
30. 10.1021/mp200463e10.1021/mp200463e ↗
31. 10.1021/bm900029810.1021/bm9000298 ↗
32. 10.1016/j.tiv.2009.09.01410.1016/j.tiv.2009.09.014 ↗
33. 10.1016/j.nano.2019.02.00210.1016/j.nano.2019.02.002 ↗
34. 10.1021/mp100104x10.1021/mp100104x ↗
35. 10.1002/VIW.2020012010.1002/VIW.20200120 ↗
36. 10.1021/acs.nanolett.0c0095310.1021/acs.nanolett.0c00953 ↗
37. 10.1002/anie.20110550810.1002/anie.201105508 ↗
38. 10.1038/srep0944510.1038/srep09445 ↗
39. 10.1038/s41467-021-24960-610.1038/s41467-021-24960-6 ↗
40. 10.1016/j.copbio.2019.10.01110.1016/j.copbio.2019.10.011 ↗
41. 10.1002/smll.20220494110.1002/smll.202204941 ↗
42. 10.1007/s10753-023-01946-810.1007/s10753-023-01946-8 ↗
43. 10.1186/s12974-020-01817-110.1186/s12974-020-01817-1 ↗
44. 10.3390/molecules2406109410.3390/molecules24061094 ↗
45. 10.1021/j100389a01010.1021/j100389a010 ↗
46. 10.1021/ja00512a00110.1021/ja00512a001 ↗
47. 10.1021/ja00315a05110.1021/ja00315a051 ↗
48. 10.1002/jcc.2003510.1002/jcc.20035 ↗
49. 10.1002/jcc.54004021110.1002/jcc.540040211 ↗
50. 10.1021/acs.jcim.8b0091110.1021/acs.jcim.8b00911 ↗
51. 10.1007/s10822-017-0091-910.1007/s10822-017-0091-9 ↗
52. 10.1016/j.bpc.2011.06.00310.1016/j.bpc.2011.06.003 ↗
53. 10.1021/bm101033g10.1021/bm101033g ↗
54. 10.1021/nl061609m10.1021/nl061609m ↗
55. 10.1021/jp309616t10.1021/jp309616t ↗
56. 10.1021/bm901298t10.1021/bm901298t ↗
57. 10.1021/acs.langmuir.8b0010510.1021/acs.langmuir.8b00105 ↗
58. 10.1002/jcc.2303110.1002/jcc.23031 ↗
59. 10.1021/acs.jctc.6b0018610.1021/acs.jctc.6b00186 ↗
60. 10.1063/1.44586910.1063/1.445869 ↗
61. 10.1021/acs.jcim.0c0139010.1021/acs.jcim.0c01390 ↗
62. 10.1063/1.47064810.1063/1.470648 ↗
63. 10.1063/1.47011710.1063/1.470117 ↗
64. 10.1038/mtna.2013.510.1038/mtna.2013.5 ↗
65. 10.1016/j.jconrel.2015.06.04110.1016/j.jconrel.2015.06.041 ↗
66. 10.1002/ejlt.20090010710.1002/ejlt.200900107 ↗
67. 10.1186/2046-1682-5-910.1186/2046-1682-5-9 ↗
68. 10.1016/j.ejcb.2020.15109510.1016/j.ejcb.2020.151095 ↗
69. 10.1038/s41467-017-00259-310.1038/s41467-017-00259-3 ↗
70. 10.1038/s41598-024-56520-510.1038/s41598-024-56520-5 ↗
71. 10.7171/jbt.19-3002-00110.7171/jbt.19-3002-001 ↗
72. 10.1146/annurev-pharmtox-061724-08062110.1146/annurev-pharmtox-061724-080621 ↗
73. Hoffmann, S.; Hewitt, P.; Koscielski, I.; Kurek, D.; Strijker, W.; Kosim, K.Validation of an MPS-based intestinal cell culture model for the evaluation of drug-induced toxicity Front. Drug Discovery 2025; Vol. 4-2024, Original Research. 10.3389/fddsv.2024.1459424.10.3389/fddsv.2024.1459424 ↗
74. 10.1016/S1369-7021(05)00746-710.1016/S1369-7021(05)00746-7 ↗